Skip to main content
. Author manuscript; available in PMC: 2015 Jul 25.
Published in final edited form as: J Vasc Surg. 2012 Jun 12;56(1):e17–e51. doi: 10.1016/j.jvs.2012.05.054
Committee Member Consultant Speaker’s Bureau Ownership/ Partnership/ Principal Research Institutional, Organizational, or Other Financial Benefit Expert Witness
Peripheral Vascular Ultrasound and Physiological Testing Writing Group
Emile R. Mohler III

  • AMAG Pharmaceuticals

  • GlaxoSmithKline

  • Merck & Co.

 None None

  • Bristol-Myers Squibb

  • GlaxoSmithKline

  • National Institutes of Health

 None None
Heather L. Gornik None None None

  • Summit Doppler Systems, Inc.

  • Fibromuscular Dysplasia Society of America (volunteer)

  • Intersocietal Commission for the Accreditation of Vascular Laboratories

  • Summit Doppler Systems, Inc. (royalties)

 None
Marie Gerhard-Herman None None None None None None
Sanjay Misra None None None

  • Johnson & Johnson

  • Merck & Co.

 None None
Jeffrey W. Olin

  • Fibromuscular Dysplasia Society of America

  • Genzyme

 None None

  • National Institutes of Health

  • Sanofi Aventis/Bristol-Myers Squibb partnership

 Colorado Prevention Center

  • 2007 Defendant, Buerger’s disease

  • 2009 Defendant, pulmonary embolism
R. Eugene Zierler

  • Intellectual Ventures

 None

  • American Registry for Diagnostic Medical Sonography

  • Joint Review Commission for Education in Diagnostic Medical Sonography

 None None None
Peripheral Vascular Ultrasound and Physiological Testing Technical Panel
Bradley S. Dixon

  • Pervasis Therapeutics

  • Proteon Therapeutics

  • Shire Pharmaceuticals

 None None

  • CardioKine Inc.

  • Hemodialysis vascular access

  • Novartis Pharmaceutical Corp.

  • Reata Pharmaceuticals

 None None
Vickie R. Driver

  • Baxter

  • Integra

  • Sanofi

 None None

  • Baxter

  • Integra

  • KCI

  • 3M

  • Celleration

  • Ogenix

 None None
Peter S. Fail None

  • Abbott

  • Daiichi Sankyo

 None None None None
Reza Fazel None None None None None None
Laura Findeiss None

  • Bayer Healthcare

 None None None None
Richard Fuchs None None None None None None
John Gillespie None None None None None None
Joseph P. Hughes None None None None None None
Cheryl Jaigobin None None None None None None
Steven A. Leers None None None None None None
Colleen Moore None None None

  • Aastrom

  • Cloysis

  • Ekos

  • Vascular Solutions

 None

  • Department of Defense
John S. Pellerito None None None None None None
Michelle L. Robbin

  • Philips Ultrasound

 None None

  • National Institutes of Health

 None None
Rita E. Shugart None None None None None None
Fred A. Weaver

  • WL Gore

 None None

  • Executive committee, HOPE4HF trial

 None None
Christopher J. White None None None None None None
Alexander S. Yevzlin None None None None None None
Peripheral Vascular Ultrasound and Physiological Testing External Reviewers
Mouaz H. Al-Mallah None None None None None None
Clifford T. Araki None None None None None None
Curtis W. Bakal None None None None None None
Phillip J. Bendick None

  • GE Ultrasound

  • Zonare Ultrasound

 None None None None
Raymond Edward Bertino None None None None None None
Robert W. W. Biederman None

  • Merck-Schering-Plough

 None

  • Merck-Schering-Plough (MRI research)

  • Osiris Steering committee (no financial support)

 None None
John Blebea None None None None None None
Andressa G. R. Borges None None None None None None
Doug Campos-Outcalt None None None None None None
Kathleen A. Carter None None None None None None
Donald E. Casey Jr None None None None None None
Alan M. Dietzek None

  • International RN Congress

 None None None None
Regina S. Druz None None None None None None
Troy Fiesinger None None None None None None
Naomi Hamburg None None None None None None
Sujith Kalathiveetil None None None None None None
Jengyu Lai None None None None None None
Carol Miranda None None None None None None
Steffen E. Petersen None None None None None None
Patricia (Tish) A. Poe None None None None None None
Robert R. Ross None None None None None None
Lawrence Rudski None None None None None None
Russell H. Samson None None None None None None
Aseem Vashist None None None None None None
James Wrobel None None None None None None

This table represents the relevant relationships with industry and other entities that were disclosed by participants at the time of participation. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Participation does not imply endorsement of this document.

*

Significant relationship.